- Home
- NODK vs ITOS Comparison
NODK vs ITOS Comparison
Compare NODK & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- ITOS
- Stock Information
- Founded
- NODK 1946
- ITOS 2011
- Country
- NODK United States
- ITOS United States
- Employees
- NODK N/A
- ITOS N/A
- Industry
- NODK Property-Casualty Insurers
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NODK Finance
- ITOS Health Care
- Exchange
- NODK Nasdaq
- ITOS Nasdaq
- Market Cap
- NODK 261.8M
- ITOS 270.7M
- IPO Year
- NODK 2017
- ITOS 2020
- Fundamental
- Price
- NODK $12.19
- ITOS $6.70
- Analyst Decision
- NODK
- ITOS Strong Buy
- Analyst Count
- NODK 0
- ITOS 3
- Target Price
- NODK N/A
- ITOS $25.67
- AVG Volume (30 Days)
- NODK 14.6K
- ITOS 553.7K
- Earning Date
- NODK 05-16-2025
- ITOS 04-28-2025
- Dividend Yield
- NODK N/A
- ITOS N/A
- EPS Growth
- NODK N/A
- ITOS N/A
- EPS
- NODK N/A
- ITOS N/A
- Revenue
- NODK $325,204,000.00
- ITOS $35,000,000.00
- Revenue This Year
- NODK N/A
- ITOS N/A
- Revenue Next Year
- NODK N/A
- ITOS $31.74
- P/E Ratio
- NODK $39.97
- ITOS N/A
- Revenue Growth
- NODK 6.97
- ITOS 177.89
- 52 Week Low
- NODK $12.02
- ITOS $4.80
- 52 Week High
- NODK $17.24
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- NODK 33.16
- ITOS 49.45
- Support Level
- NODK $12.30
- ITOS $6.58
- Resistance Level
- NODK $13.07
- ITOS $7.80
- Average True Range (ATR)
- NODK 0.41
- ITOS 0.51
- MACD
- NODK -0.02
- ITOS -0.03
- Stochastic Oscillator
- NODK 11.68
- ITOS 32.10
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.